Baxter International (BAX) 2025 Earnings Quality Report

Grade: F — Multiple Structural Red Flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-12, fiscal year ended December 31, 2025) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP — Clean opinion (2 Critical Audit Matters)

One-line verdict: Baxter's 2025 is the story of a company in the middle of a strategic reset. After selling the Kidney Care business (Vantive) to Carlyle on January 31, 2025 for $3.80B — following the 2023 sale of the BioPharma Solutions business for $3.96B — the remaining continuing operations are struggling to find stable ground. Continuing-operations net income was negative $957M in 2025, the third consecutive year of losses (excluding the one-time gain year), and the 10-K discloses two fresh impairments totaling $775M: a $485M goodwill impairment on the Front Line Care reporting unit and a $290M impairment of the Welch Allyn trade name. Gross margin collapsed from 37.5% to 30.1% — a 7.4 percentage point move. Our 18-check screen returned four red flags and three watch items — the weakest result of this batch. CFFO/NI cannot be computed meaningfully given the losses, cash covers only 20% of the $9.8B in remaining debt, goodwill plus intangibles of $9.3B exceeds stockholders' equity of $6.1B by 1.5x, and Debt/EBITDA of 12.8x places Baxter in the textbook "financial stress" zone. The Altman Z-Score of 3.89 is paradoxically in the safe zone — but only because retained earnings remain positive from years of prior profitability. The underlying trend is what matters. PwC's clean opinion with two CAMs acknowledges the judgment involved in valuing the impaired assets.

Business: Three Segments After Back-to-Back Divestitures

Per Item 1 of the 10-K: "Under this operating model, our business is currently comprised of three reportable segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals."

The two divestitures dominate the recent history:

Baxter used the proceeds to reduce debt significantly. Per the cash flow disclosures: "repayment of the $750 million principal outstanding under the 2026 Notes (inclusive of the cash tender offer and the subsequent satisfaction and discharge with respect to the remaining 2026 Notes), the cash tender offer on the 2027 Notes in an aggregate purchase price of $600 million and repaid $645 million under the Term Loan Facility."

The continuing operations — Medical Products & Therapies (IV solutions, parenteral nutrition, surgical technologies), Healthcare Systems & Technologies (hospital beds, connected care platforms including Welch Allyn), and Pharmaceuticals (injectable drug compounding) — generated the $11.24B in 2025 revenue from which we derive this analysis.

Profitability: Margin Collapse

Per the consolidated statements of operations (continuing operations):

*2023 net income included the BPS divestiture gain of approximately $2.59B net of tax — operating results were break-even at best.

The gross margin collapse from 37.5% to 30.1% — a 740 basis point decline in a single year — is the most important number in this filing. On revenue of $11.24B, that movement represents approximately $830M of gross profit lost. The B4 check correctly flags this as WATCH (the threshold is triggered on swings >3pp). At 30.1%, Baxter's gross margin is at the bottom of medical device peers.

The SG&A / gross profit ratio of 85.5% triggers the B3 watch — SG&A is almost consuming the entire gross profit. This is structurally unsustainable.

Net loss of $957M in 2025 is materially worse than the $649M loss in 2024. Over three years of meaningful operating activity, Baxter has lost close to $2B in continuing operations net income before divestiture gains.

The Two Impairments Per PwC's CAMs

PwC has audited Baxter since 1985 — 40 years. The 2025 audit identified two Critical Audit Matters, both impairment-related:

CAM 1: Front Line Care Goodwill Impairment — $485M

Per the audit report: "the Company's consolidated goodwill balance as of December 31, 2025 was $4,929 million, and the goodwill associated with the Front Line Care reporting unit was $1,520 million... In connection with the annual goodwill impairment assessment, management recorded a $485 million goodwill impairment related to the Front Line Care reporting unit."

PwC explains the judgment: "The principal considerations for our determination that performing procedures relating to the goodwill impairment assessment of the Front Line Care reporting unit is a critical audit matter are (i) the significant judgment by management when developing the fair value estimate of the reporting unit; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management's significant assumptions related to the revenue growth rates, forecasted EBITDA margins, discount rate, and terminal growth rate."

The Front Line Care reporting unit includes the Welch Allyn diagnostic device business. After this impairment, $1,520M - $485M = $1,035M of goodwill remains on this reporting unit, and PwC's CAM disclosure indicates the remaining balance is close to fair value.

CAM 2: Welch Allyn Trade Name Impairment — $290M

Per the audit report: "the Company's consolidated trade names indefinite-lived intangible asset balance as of December 31, 2025 was $390 million... In connection with the annual impairment assessment, management recognized a pre-tax impairment charge of $290 million to reduce the carrying amount of the Welch Allyn trade name, an indefinite-lived intangible asset, to its estimated fair value."

The Welch Allyn acquisition (completed in 2015 for $2.05B) has now been written down substantially. The $290M trade name impairment combined with the goodwill write-down means Baxter has recognized at least $775M in impairments attributable to the Welch Allyn/Front Line Care operations in 2025 alone.

Both CAMs signal the same fundamental issue: the fair value of these businesses has declined materially, and management's "revenue growth rates, discount rate, and royalty rate" assumptions are at the edge of what PwC was willing to sign off on.

Cash Flow: Down 51% in Two Years

Per the consolidated statements of cash flows:

C1 fails: CFFO has been below net income for three consecutive years (the 2023 ratio of 0.65 reflects the large one-time divestiture gain boosting net income; 2024 and 2025 are both negative net income years).

CFFO itself has dropped from $1.73B to $845M over two years — a 51% decline. Free cash flow of $323M in 2025 barely covered the $348M dividend, which Baxter already cut from $590M in 2024. A further dividend cut or suspension would not be surprising.

The positive note: because of the Vantive divestiture proceeds used for debt paydown, interest expense fell from $508M in 2023 to $290M in 2025 — saving about $220M annually.

The Capital Structure: C4, D1, D2 All Fail

Three balance sheet checks fail simultaneously:

The D2 fail is particularly notable because EBITDA of $766M is crushed by the impairments — if we add back the $775M in impairments, "adjusted EBITDA" would be closer to $1.5B, producing a more normal 6.5x Debt/EBITDA. Still high, but not "stress zone." This is the right way to think about the D2 signal: the accounting numbers show stress, the cash flow numbers show a turnaround in progress.

The 18-Point Screening

Beneish M-Score components: DSRI 1.048, GMI 1.246 (gross margin index showing major deterioration), AQI 0.934, SGI 1.057 (modest growth), DEPI 1.015, SGAI 0.921, TATA -0.0899, LVGI 0.947.

The GMI of 1.246 flags the gross margin deterioration (a GMI > 1.0 means margin worsened). The M-Score still passes because the other components are normal and TATA is low — Baxter is not aggressively accruing. The issue is operational, not accounting.

Altman Z-Score 3.89: Components X1 working capital/assets 0.08, X2 retained earnings/assets 0.56, X3 EBIT/assets 0.04, X4 equity/liabilities 0.44. The X2 (retained earnings) carries the score — Baxter has decades of prior profitability in retained earnings that mask the current operating distress.

Key Risks from the 10-K (Item 1A)

1. Operational Margin Pressure

The 740 bp gross margin decline from 37.5% to 30.1% reflects a combination of (a) input cost inflation, (b) the loss of economies of scale after the Kidney Care divestiture (shared infrastructure costs spread across a smaller revenue base), and (c) hurricane-related costs. The 10-K discloses hurricane-related disruption affecting operations.

2. Pricing Pressure in Hospital Supplies

Baxter's continuing businesses — IV solutions, parenteral nutrition, hospital beds — serve hospitals that are themselves financially stressed. Pricing pressure from GPOs (Group Purchasing Organizations) and integrated delivery networks has been relentless.

3. Impairment Risk on Remaining Goodwill

After the $485M Front Line Care impairment, $4.93B of goodwill remains on the balance sheet. PwC's CAM indicates the Front Line Care remaining goodwill ($1,035M after write-down) is close to fair value — meaning a further deterioration in assumptions could trigger additional write-downs.

4. Debt Service Risk

Interest coverage of 0.6x in 2025 is below 1.0x. Baxter has been actively paying down debt (from $17.2B in 2022 to $9.8B in 2025 — a 43% reduction) using divestiture proceeds, which is the right move. But the covenant environment and refinancing risk on remaining debt warrants monitoring.

5. Regulatory and Product Quality

As a large-volume medical device and IV solutions manufacturer, Baxter faces ongoing FDA inspection risk, product recall risk, and quality assurance exposure. The 10-K discloses these risks across Item 1A.

Key Financial Trends (4-Year)

*2023 includes one-time gain from BPS divestiture.

Summary

Grade: F. Four red flags, three watch items, and two auditor-flagged impairments make Baxter the most flagged name in this batch.

The screen output is unusual — almost every check that can fail, fails. The 18-point framework was designed to detect this exact pattern:

Two countervailing factors provide context:

First, the Altman Z-Score of 3.89 is comfortably in the safe zone because retained earnings from decades of prior profitability ($11.3B+ per the X2 component) still dominate the assets base. This is not a company near bankruptcy — it is a company with balance sheet strength from the past being eroded by current operating losses.

Second, management has aggressively divested. Over two years, Baxter sold BPS for $3.96B (2023) and Vantive/Kidney Care for $3.80B (2025). The proceeds paid down debt from $17.2B to $9.8B — a $7.4B reduction. Interest expense fell from $508M to $290M. The company is executing a real strategic restructuring.

But the core continuing operations are struggling. Two PwC-flagged impairments totaling $775M show Welch Allyn is worth materially less than its carrying value. Gross margin dropped 740 basis points. CFFO fell 51% over two years. The dividend was already cut from $590M to $348M.

The Beneish M-Score of -2.67 passes — Baxter is not manipulating earnings. The F-Score fraud probability of 0.48% is low. This is not an accounting problem. It is an operating problem that the impairments, the gross margin compression, and the CFFO decline all confirm.

Read the 10-K. Read Notes 1 and 4 on goodwill and impairment. Read the segment footnotes on Front Line Care. Read the hurricane disclosure. Then decide whether the Vantive proceeds and debt paydown are enough to stabilize the continuing operations, or whether additional impairments and restructuring are ahead.

**Disclaimer**: This report is based on Baxter International's fiscal year 2025 10-K filed with the SEC on February 12, 2026. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags using an 18-point forensic framework. Grade F means multiple material concerns were identified that warrant thorough investigation.